Investigator

Yasin Durmuş

Assoc.Prof. · Samsun Training and Research Hospital, Department of Gynecological Oncology

YDYasin Durmuş
Papers(3)
Plexiform neurofibrom…Factors associated wi…Can we predict surgic…
Collaborators(1)
Salih Taskin
Institutions(2)
Msd TurkiyeAnkara University

Papers

Plexiform neurofibroma infiltrating uterine cervix and parametrium, causing hydronephrosis: A case report and review of the literature

Abstract Neurofibromatosis Type 1 is a genetic disorder resulting in RAS pathway activation. As a result, risk of developing both benign and malignant neoplasms is higher, compared with the general population. Plexiform neurofibromas are benign tumors of the peripheral nerve sheath affecting 40%–50% of patients with neurofibromatosis Type 1. Cervical‐parametrial plexiform neurofibroma is a very rare neoplasm. Here we present the ninth case in the literature. A 37‐year‐old woman presented with chronic pelvic pain and a pelvic mass that was 73 × 33 mm in size. Most of the mass was located between the proximal vagina‐cervix and the bladder. It was infiltrating the bilateral parametrium and the pararectal tissues. There was hydronephrosis on the right side and her right kidney was atrophic. The tumor would likely also cause obstruction on the left side. We performed a type B radical hysterectomy, right salpingo‐oophorectomy, left salpingectomy, cystoscopy, left ureterorenoscopy, and left ureteral double‐j catheterization, in addition to resection of the tumor, which was located between the cervix and bladder. She was followed for 11 months without any tumor relapse. The left kidney remained normal in the follow‐up period. To our knowledge, this is the first publication reporting the neurofibromatosis Type1 mutation c.7615 + 6 T>C as a pathogenic variant. In this case, we showed that plexiform neurofibromas and neurofibromatosis should be taken into account, when a pelvic mass adjacent to the uterine cervix is diagnosed, particularly if the tumor tends to accompany the peripheral nerve tracts. Surgical treatment of cervical‐parametrial plexiform neurofibromas is recommended in certain circumstances and a multidisciplinary approach may help to determine the optimal management.

Factors associated with the involvement of lymph nodes in low‐grade serous ovarian cancer

AbstractBackground and ObjectivesEvaluating nodal metastases in low‐grade serous ovarian cancer (LGSOC) patients.MethodsWomen with LGSOC who had undergone primary cytoreductive surgery comprising systematic pelvic‐paraaortic lymphadenectomy were included. Data were obtained retrospectively from 12 oncology centers.ResultsOne hundred and forty‐eight women with LGSOC who had undergone comprehensive surgical staging were included. Seventy‐one (48.0%) patients had metastatic lymph nodes. Preoperative serum CA‐125 levels of ≥170 U/ml (odds ratio [OR]: 3.84; 95% confidence interval [CI]: 1.22–12.07; p = 0.021) and presence of lymphovascular space invasion (LVSI) (OR: 13.72; 95% CI: 3.36–55.93; p < 0.001) were independent predictors of nodal metastasis in LGSOC. Sixty (40.5%) patients were classified to have apparently limited disease to the ovary/ovaries. Twenty (33.3%) of them were upstaged after surgical staging. Twelve (20.0%) had metastatic lymph nodes. Presence of LVSI (OR: 12.96; 95% CI: 1.14–146.43; p = 0.038) and preoperative serum CA‐125 of ≥180 U/ml (OR: 7.19; 95% CI: 1.35–38.12; p = 0.02) were independent predictors of lymph node metastases in apparent Stage Ⅰ disease.ConclusionsClinicians may consider to perform a reoperation comprising systematic lymphadenectomy in patients who had apparently limited disease to the ovary/ovaries and had not undergone lymphadenectomy initially. Reoperation may be considered particularly in patients whose preoperative serum CA‐125 is ≥180 U/ml and/or whose pathological assessment reported the presence of LVSI.

17Works
3Papers
1Collaborators

Positions

2022–

Assoc.Prof.

Samsun Training and Research Hospital · Department of Gynecological Oncology